



**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T: 91 80 2808 2808  
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/EA/2023-24/84

September 01, 2023

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code – 532523</b>	<b>Scrip Symbol – Biocon</b>

**Subject: Appointment of Independent Director**

Dear Sir/Madam,

This is with reference to our letter dated August 10, 2023, wherein it was informed that the Board of Directors at its meeting held on Thursday, August 10, 2023, had approved the appointment of Mr. Nicholas Robert Haggart (DIN: 08518863) as an Additional Director (Category: Non-Executive, Independent Director) of the Company subject to registration of his name in the Independent Director's databank maintained by the Indian Institute of Corporate Affairs (IICA) and accordingly, his appointment on the Board will be effective from such date.

The Board also approved the appointment of Mr. Nicholas Robert Haggart as an Independent Director of the Company, not liable to retire by rotation, for a term commencing from the date of registration of his name in the Independent Director's databank till the conclusion of 48th Annual General Meeting to be held in the year 2026, subject to approval of the shareholders of the Company.

In this regard, please note that Mr. Nicholas Robert Haggart is now registered with the Independent Director's databank w.e.f. today i.e. September 01, 2023, and accordingly his appointment as an Additional Director (Category: Non-Executive, Independent Director) is effective from today.



Further, the appointment of Mr. Nicholas Robert Haggart as an Independent Director shall commence from September 01, 2023, till the conclusion of 48<sup>th</sup> Annual General Meeting to be held in the year 2026, subject to approval of the shareholders of the Company.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,  
For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

### **BRIEF PROFILE OF MR. NICHOLAS ROBERT HAGGAR**



Mr. Nicholas Robert Haggar, 58 years, has over 30 years of experience in leading and building pharmaceutical and healthcare enterprises and has been successfully guiding innovation and increasing access to medicines, with deep commitment to patients, compliance, quality and sustainability.

As the Chief Executive Officer (CEO) of Zentiva, Mr. Haggar built a vibrant and fast-growing business facilitating 11 acquisitions (including 2 transformational in 4 years). Later, he was transitioned from CEO to Non-Executive Director of Zentiva.

Mr. Haggar has earned an MBA from Cranfield Institute, UK. During the course of 30 years of professional experience, Mr. Haggar has been associated with Ranbaxy International, Sandoz International GmbH and Chemo MabXience.

Mr. Haggar currently serves as a CEO and Founder at HealthQube Limited and as an Advisor to Insud, Formycon, Medicines for Europe and Advent International.